Cargando…
Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer
BACKGROUND: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (tac) compared with 5-fluorouracil, doxorubicin, and c...
Autores principales: | Mittmann, N., Verma, S., Koo, M., Alloul, K., Trudeau, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826781/ https://www.ncbi.nlm.nih.gov/pubmed/20179798 |
Ejemplares similares
-
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008) -
ESTRO ACROP guidelines for positioning, immobilisation and position verification of head and neck patients for radiation therapists
por: Leech, Michelle, et al.
Publicado: (2017) -
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
por: Lecour, Sandrine, et al.
Publicado: (2021) -
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000
por: Basuyau, J P, et al.
Publicado: (2003) -
Adjuvant hormonal therapy for stage I endometrial cancer
por: Gien, L., et al.
Publicado: (2008)